03:40 PM EST - Medicago Inc. : and The Infectious Disease Research Institute, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, today reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate. Medicago Inc.
shares T.MDG are trading up $0.03 at $0.55.
